Skip to main content


BioVeris announced this week that it has launched eight new products for use in life science research to measure potential immune response to protein-based therapeutics that are in development.
According to the company, two of the products are pharmacodynamic biomarkers, which detect human IL-2 and TNF-alpha and measure cytokine levels that may be elevated due to a drug treatment response.
The other six products can be used for immunogenicity testing, assay development, and hybridoma screening. “The products are composed of a panel of antibodies that are prelabeled with BioVeris’ detection label BV-TAG Plus and may be used to quantitate and characterize the following mouse antibodies: IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3,” the company said in a statement.

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.